<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/61AB1C74-15B8-42AF-ABDF-43C393FB8599"><gtr:id>61AB1C74-15B8-42AF-ABDF-43C393FB8599</gtr:id><gtr:name>Lohmann Therapeutic Systems</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/61AB1C74-15B8-42AF-ABDF-43C393FB8599"><gtr:id>61AB1C74-15B8-42AF-ABDF-43C393FB8599</gtr:id><gtr:name>Lohmann Therapeutic Systems</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/50E04830-F450-4726-B283-12F7E2C46474"><gtr:id>50E04830-F450-4726-B283-12F7E2C46474</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Woolfson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AF82F35A-7B02-402E-B41C-D30667FD003C"><gtr:id>AF82F35A-7B02-402E-B41C-D30667FD003C</gtr:id><gtr:firstName>Ryan</gtr:firstName><gtr:surname>Donnelly</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FK020234%2F1"><gtr:id>9CA6AD0D-FDEF-4B02-9D8E-74ED56AE8376</gtr:id><gtr:title>Manufacture and applicator technologies for commercialisation of polymeric microneedle arrays</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/K020234/1</gtr:grantReference><gtr:abstractText>We have developed a novel type of transdermal patch with tiny needles on its surface that painlessly and without causing bleeding by-pass the skin's stratum corneum barrier. These needles either dissolve quickly, leaving tiny holes in the skin, which will let proteins and peptides enter the body, or swell, turning into a jelly-like material that keeps the holes open and allows continuous delivery. Our technology is unique and could potentially revolutionise delivery of medicines. Interestingly, we have also found that our swellable microneedles can extract fluid from the skin. This permits us to monitor the levels of drugs in a person's blood without actually taking blood samples, meaning that adverse events and complications arising from blood sampling could be prevented, to the benefit of patients Worldwide. In this project, we will focus on moving our microneedle production from laboratory scale to industrial scale and design and validation of a low-cost user friendly applicator.</gtr:abstractText><gtr:fund><gtr:end>2015-08-07</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2013-08-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>709445</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lohmann Therapeutic Systems</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Industial partnerships</gtr:description><gtr:id>F376C065-F192-456C-9868-138B1E194E1B</gtr:id><gtr:impact>Scalable methods of microneedle manufacture, novel quality control tests and successful vaccination of animal models</gtr:impact><gtr:partnerContribution>Industrial expertise in these disciplines</gtr:partnerContribution><gtr:piContribution>Collaborative working on microneedle scale-up, quality control and vaccination</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>190499</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A transdermal microneedle delivery system for methotrexate treatment in paediatric rheumatic disease: Production and evaluation</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>23B6E3E3-E411-4138-9304-572E3880FAC3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Microneedle-mediated delivery of rilpivirine and gentamicin</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Program for Appropriate Technology in Health (PATH)</gtr:fundingOrg><gtr:id>7D846668-7BE0-46DB-995C-E238DF416DA9</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Yes. Working with L'OREAL, Randox and Lohmann Therapie-Systeme AG to move our technology to market</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>55FB8646-C8A1-431A-91A4-C1DD9570FD6C</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Project is now complete and went extremely well. We successfully devised scalable methods for microneedle production and a novel means of microneedle application. These have now been taken on my our new manufacturing partner Lohmann Therapie-Systeme AG</gtr:description><gtr:exploitationPathways>Working with a number of international companies to commercialise our microneedles</gtr:exploitationPathways><gtr:id>192F3B3A-ADA6-4354-AF3C-85987F0C8F53</gtr:id><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12007C67-A1F1-4210-BE32-19914D1778BD"><gtr:id>12007C67-A1F1-4210-BE32-19914D1778BD</gtr:id><gtr:title>A facile system to evaluate in vitro drug release from dissolving microneedle arrays.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff70d39c882d0c4290a99fb1f4a35f04"><gtr:id>ff70d39c882d0c4290a99fb1f4a35f04</gtr:id><gtr:otherNames>Larra?eta E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90720CAD-6F86-4592-8E61-2B742A4AE774"><gtr:id>90720CAD-6F86-4592-8E61-2B742A4AE774</gtr:id><gtr:title>Hydrogel-forming microneedles increase in volume during swelling in skin, but skin barrier function recovery is unaffected.</gtr:title><gtr:parentPublicationTitle>Journal of pharmaceutical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3549</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A63EB706-9A1C-43BA-97D2-46B1C5BB8D4B"><gtr:id>A63EB706-9A1C-43BA-97D2-46B1C5BB8D4B</gtr:id><gtr:title>A novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6216f40eb0fb368ba0022d54d8f8b48"><gtr:id>d6216f40eb0fb368ba0022d54d8f8b48</gtr:id><gtr:otherNames>Lutton RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD7AFF17-C170-42CB-AF19-52982F94C8AE"><gtr:id>FD7AFF17-C170-42CB-AF19-52982F94C8AE</gtr:id><gtr:title>Laser-engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a5b7048b696adf8904e091eaf21f562b"><gtr:id>a5b7048b696adf8904e091eaf21f562b</gtr:id><gtr:otherNames>McCrudden MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AF143005-13D7-4B3C-8EE7-B3A2DB8AB1A9"><gtr:id>AF143005-13D7-4B3C-8EE7-B3A2DB8AB1A9</gtr:id><gtr:title>Hydrogel-forming microneedle arrays can be effectively inserted in skin by self-application: a pilot study centred on pharmacist intervention and a patient information leaflet.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/751F78CE-D306-4AA6-A0F2-901F62A86D77"><gtr:id>751F78CE-D306-4AA6-A0F2-901F62A86D77</gtr:id><gtr:title>Microneedle characterisation: the need for universal acceptance criteria and GMP specifications when moving towards commercialisation.</gtr:title><gtr:parentPublicationTitle>Drug delivery and translational research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6216f40eb0fb368ba0022d54d8f8b48"><gtr:id>d6216f40eb0fb368ba0022d54d8f8b48</gtr:id><gtr:otherNames>Lutton RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2190-393X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F95AC55D-F413-4954-92D3-0F64450FC836"><gtr:id>F95AC55D-F413-4954-92D3-0F64450FC836</gtr:id><gtr:title>The role of microneedles for drug and vaccine delivery.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55beff7f925ffc49ab40d95868293a40"><gtr:id>55beff7f925ffc49ab40d95868293a40</gtr:id><gtr:otherNames>Quinn HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-5247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B037F5D-54FA-47D6-85B7-F0048076C810"><gtr:id>2B037F5D-54FA-47D6-85B7-F0048076C810</gtr:id><gtr:title>Microneedle arrays as transdermal and intradermal drug delivery systems: Materials science, manufacture and commercial development</gtr:title><gtr:parentPublicationTitle>Materials Science and Engineering: R: Reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff70d39c882d0c4290a99fb1f4a35f04"><gtr:id>ff70d39c882d0c4290a99fb1f4a35f04</gtr:id><gtr:otherNames>Larra?eta E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D1648F7-CA61-4C8D-A176-8E6BAD87DF1D"><gtr:id>2D1648F7-CA61-4C8D-A176-8E6BAD87DF1D</gtr:id><gtr:title>A proposed model membrane and test method for microneedle insertion studies.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ff70d39c882d0c4290a99fb1f4a35f04"><gtr:id>ff70d39c882d0c4290a99fb1f4a35f04</gtr:id><gtr:otherNames>Larra?eta E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9A2CDF1F-7EEB-41C0-8AF1-96B64D215EE8"><gtr:id>9A2CDF1F-7EEB-41C0-8AF1-96B64D215EE8</gtr:id><gtr:title>Patient safety and beyond: what should we expect from microneedle arrays in the transdermal delivery arena?</gtr:title><gtr:parentPublicationTitle>Therapeutic delivery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e163238e93b7eff5a965f10b748b7492"><gtr:id>e163238e93b7eff5a965f10b748b7492</gtr:id><gtr:otherNames>Donnelly RF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-5990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4C8BD344-2BFC-49A9-9120-C1A9FDC18F43"><gtr:id>4C8BD344-2BFC-49A9-9120-C1A9FDC18F43</gtr:id><gtr:title>Considerations in the sterile manufacture of polymeric microneedle arrays.</gtr:title><gtr:parentPublicationTitle>Drug delivery and translational research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a5b7048b696adf8904e091eaf21f562b"><gtr:id>a5b7048b696adf8904e091eaf21f562b</gtr:id><gtr:otherNames>McCrudden MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2190-393X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/K020234/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>